 Upidacetanib is a new type of medication called a janus kinase, JAK, inhibitor which has been approved for the treatment of rheumatoid arthritis, RA. It works by blocking certain proteins involved in inflammation and joint damage caused by RA. Studies show it can be effective in treating RA, regardless of whether the patient is taking methotrexate or not. Additionally, studies have found that upidacetanib is more effective than other treatments such as a badisept and a dallomumab. This article was authored by Raimond Sanmarti and Hector Karamanas.